Geron (NASDAQ:GERN) Raised to “Strong-Buy” at Leerink Partnrs

Leerink Partnrs upgraded shares of Geron (NASDAQ:GERN) to a strong-buy rating in a research report released on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Geron’s Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.33) EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.07 EPS, FY2025 earnings at $0.12 EPS and FY2026 earnings at $0.39 EPS.

A number of other research analysts have also weighed in on GERN. Barclays initiated coverage on Geron in a research note on Monday, June 10th. They set an overweight rating and a $9.00 price target on the stock. Wedbush restated an outperform rating and issued a $8.00 price target on shares of Geron in a report on Thursday, August 8th. StockNews.com raised shares of Geron to a sell rating in a research note on Monday, August 5th. Needham & Company LLC reissued a buy rating and issued a $6.00 target price on shares of Geron in a research report on Friday, August 9th. Finally, Stifel Nicolaus upped their price target on shares of Geron from $6.00 to $7.00 and gave the stock a buy rating in a research report on Monday, June 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Geron currently has an average rating of Moderate Buy and an average target price of $7.06.

Geron Trading Up 1.2 %

Geron stock opened at $4.39 on Monday. The stock has a market cap of $2.60 billion, a PE ratio of -12.54 and a beta of 0.50. The company has a current ratio of 3.61, a quick ratio of 3.60 and a debt-to-equity ratio of 0.12. The stock has a 50-day moving average price of $4.57 and a 200 day moving average price of $3.91. Geron has a 52 week low of $1.64 and a 52 week high of $5.34.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.10). Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The business had revenue of $0.88 million during the quarter, compared to analyst estimates of $0.34 million. During the same quarter in the previous year, the business posted ($0.09) earnings per share. The company’s revenue was up 2941.4% on a year-over-year basis. Equities research analysts predict that Geron will post -0.35 earnings per share for the current fiscal year.

Insider Activity at Geron

In related news, COO Andrew J. Grethlein sold 674,348 shares of Geron stock in a transaction on Monday, July 8th. The shares were sold at an average price of $4.56, for a total transaction of $3,075,026.88. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 3.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Geron

A number of institutional investors and hedge funds have recently bought and sold shares of GERN. National Bank of Canada FI lifted its position in shares of Geron by 1,200.0% during the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 6,000 shares in the last quarter. Crewe Advisors LLC increased its position in shares of Geron by 870.0% during the first quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 8,700 shares during the last quarter. Kingsview Wealth Management LLC acquired a new position in shares of Geron in the first quarter worth about $34,000. American Trust purchased a new position in Geron in the first quarter valued at about $38,000. Finally, CIBC Asset Management Inc grew its stake in Geron by 32.7% during the 2nd quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 3,805 shares in the last quarter. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.